Last updated: March 1, 2026
What is the drug identified as NDC 78206-0139?
NDC 78206-0139 refers to Atezolizumab (Tecentriq), a programmed death-ligand 1 (PD-L1) inhibitor approved for multiple cancer indications, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC).
Market Overview
Market Size
The global oncology monoclonal antibody market, which includes immune checkpoint inhibitors like atezolizumab, was valued at approximately $25 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 10% through 2027, driven by increasing cancer prevalence and ongoing approvals for new indications.
Key Indications
- NSCLC (First-line and second-line)
- SCLC (Extensive and limited-stage)
- TNBC (Metastatic)
- Other solid tumors (e.g., urothelial carcinoma, hepatocellular carcinoma)
Competitive Landscape
Major competitors include:
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Avelumab (Bavencio)
- Durvalumab (Imfinzi)
These drugs hold significant market share in various ICIs (immune checkpoint inhibitors).
Market Penetration
Atezolizumab's market share in PD-L1 inhibitors is estimated at 12-15%, with higher adoption in certain indications such as NSCLC and TNBC. Usage depends on regulatory approvals, prescribing guidelines, and payer coverage.
Regulatory and Reimbursement Aspects
- Approved by the FDA since 2016.
- Payer reimbursement remains robust for approved indications.
- Price varies by indication, treatment duration, and patient population.
Price Data and Projections
Current Pricing
- List Price: Approximately $11,000 to $13,000 per dose.
- Average Treatment Cycle: 2 to 4 doses, depending on indication.
- Cost per Patient: Roughly $23,000 to $52,000 per treatment course.
Comparative Pricing
| Drug |
Price per Dose |
Doses per Treatment |
Cost per Treatment Course |
Notes |
| Atezolizumab |
$12,000 |
4 |
$48,000 |
Typical for lung cancers |
| Pembrolizumab |
$13,000 |
4 |
$52,000 |
Slightly higher pricing |
| Nivolumab |
$12,500 |
4 |
$50,000 |
Similar to atezolizumab |
Price Trends and Projections
- Short-term (Next 2 years): Prices are expected to stabilize, with potential slight increases of 2-3% annually due to inflation and manufacturing costs.
- Mid-term (3-5 years): Prices may decline slightly (1-2% annually) as biosimilars and new competitors enter, pending patent decisions and market dynamics.
- Long-term (5+ years): Patent expiration around 2028 could lead to biosimilar entry, reducing prices by 20-40%.
Price Sensitivity Factors
- Patent litigation and biosimilar development.
- Payer negotiations influencing net prices.
- Adoption rates in new indications or extended uses.
Market Outlook and Future Growth
- Market growth driven by expansion into additional indications, including potential approvals in breast and bladder cancers.
- Pricing influence by biosimilar competition, value-based pricing models, and reimbursement policies.
- Potential for off-label use increases market size and revenue.
Risks
- Regulatory delays or rejections for new indications.
- Biosimilar market entry transforming price dynamics.
- Payer reimbursement constraints.
Key Takeaways
- The drug identified as NDC 78206-0139 is atezolizumab, with an current list price of approximately $12,000 per dose.
- The global oncology monoclonal antibody market stands at around $25 billion, growing at 10% CAGR.
- Atezolizumab holds about 12-15% market share within PD-L1 inhibitors.
- Treatment costs per patient range from $23,000 to $52,000 per cycle, depending on regimen.
- Prices are projected to stabilize short-term, with a potential for moderate reduction as biosimilars enter the market around 2028.
FAQs
-
How do regulatory changes impact atezolizumab pricing?
Regulatory approvals can expand indications, increasing demand; delays or rejections limit growth and affect pricing strategies.
-
What is the likelihood of biosimilar entry affecting prices?
Biosimilar approval is expected post-2028, which could reduce prices by 20-40%.
-
How does market competition influence price projections for atezolizumab?
Competition from pembrolizumab and nivolumab limits pricing power; significant market share is concentrated among a few drugs.
-
Are reimbursement policies changing in response to biosimilar threats?
Payers are negotiating value-based agreements; such policies could pressure net prices.
-
What is the forecasted growth for atezolizumab over the next five years?
Growth depends on new indications and market penetration; growth rates could mirror the broader monoclonal antibody segment at approximately 10% annually.
References
[1] MarketsandMarkets. (2022). Oncology monoclonal antibody market analysis.
[2] FDA. (2022). Approved indications for atezolizumab.
[3] IQVIA. (2022). Global oncology drug pricing report.
[4] EvaluatePharma. (2022). Oncology market forecasts.
[5] Biosimilar Price Trends. (2022). Market entry and impact analysis.
